ICU Medical, Inc. — Q3 2018 Form 10-Q
Business context and period. The filing covers the quarter and nine months ended September 30, 2018. ICU Medical develops, manufactures, and sells infusion therapy and critical-care products. Results reflect ongoing integration of Pfizer’s Hospira Infusion Systems (HIS) business, acquired in February 2017. Prior-year periods are not fully comparable because HIS contributed for only part of 2017 and certain 2017 revenue was reported as “Other.”
Financial performance
- Q3 revenue: $327.2 million, down 4.7% from $343.2 million. Infusion Consumables grew 27.1% to $117.8 million; IV Solutions fell 20.4% to $114.4 million. Infusion Systems declined 1.6% to $81.5 million, and Critical Care increased 4.7% to $13.5 million.
- Nine-month revenue: $1.060 billion, up 14.9% from $922.5 million. Growth included acquisition-period and product-line classification effects; Consumables rose 47.0%, IV Solutions 5.0%, Infusion Systems 30.0%, and Critical Care 9.4%.
- Margins and earnings: Q3 gross profit was $134.6 million, with gross margin of 41.1% versus 32.5%. Operating income was $0.8 million versus an operating loss of $3.7 million; net income was $0.2 million versus $0.1 million, or $0.01 diluted EPS in both periods. For nine months, gross margin was 41.1% versus 31.3%, operating income was $33.8 million versus an operating loss of $56.6 million, and net income was $36.1 million versus $18.9 million, or $1.67 diluted EPS versus $0.92.
- Cash flow: Nine-month operating cash flow was $110.3 million, up from $69.9 million. Investing activities used $84.3 million, including $75.1 million in property and equipment purchases; financing activities provided $8.1 million. Cash and cash equivalents increased by $28.7 million during the period.
- Liquidity and debt: Cash, cash equivalents, and investment securities totaled $358.7 million at September 30, 2018, versus $314.7 million at year-end 2017. Current assets were $913.3 million and current liabilities $202.5 million. No borrowings were outstanding under the $150 million revolving facility, which was available through 2022; the Pfizer seller note had been repaid by year-end 2017. The company reported compliance with credit covenants.
- Other balance-sheet items: The contingent HIS earn-out liability was $47.5 million, up from $27.0 million at year-end. Related-party receivables, primarily involving Pfizer, were $70.4 million. Stockholders’ equity was $1.260 billion.
Material changes, unusual items, and outlook
- Gross-margin improvement was attributed primarily to product mix, higher Consumables sales, factory efficiencies, and the prior-year impact of purchase-accounting inventory step-up.
- Q3 restructuring, strategic transaction, and integration expenses totaled $24.0 million; $23.5 million related primarily to HIS integration. Nine-month expenses were $64.3 million.
- A $28.9 million charge in Q1 followed resolution of a dispute with a product partner and a redefinition of the contractual arrangement. The company says it is no longer subject to the related future minimum purchase obligations.
- Changes in the fair value of the HIS earn-out generated operating expense of $18.5 million in Q3 and $20.5 million for nine months. Pfizer may receive up to $225 million in cash based on combined-company performance over the three years ending December 31, 2019; the final amount is not yet determinable.
- Adoption of ASC 606 increased opening retained earnings by $6.3 million. Compared with the former standard, ASC 606 reduced reported Q3 revenue by $13.5 million and gross profit by $9.9 million; nine-month revenue was lower by $3.3 million and gross profit by $0.8 million. 2017 comparatives were not restated.
- Management estimated 2018 capital expenditures of approximately $100 million, primarily to support manufacturing and IT. It stated that available cash and expected operating cash flow should fund operations for at least the next 12 months; this is not revenue or earnings guidance.
- Key risks include customer and distributor concentration, demand and pricing changes, integration and execution, foreign-exchange exposure, and litigation. ICU was added as a defendant to a saline-solution antitrust complaint; related indemnification claims involve Pfizer. The company also disclosed government subpoenas concerning saline-solution business practices and Sapphire infusion pumps. Management did not expect unsettled legal proceedings to materially adversely affect financial position or results, but outcomes are uncertain.
- The company reported a net euro asset position of approximately €86.8 million and does not currently hedge its euro exposure. A 10% currency movement would affect specified consolidated balance-sheet items by approximately $10.1 million, according to the filing.
Important facts for investors to verify
- Whether the Q3 IV Solutions decline and shipment shutdown for HIS systems integration were temporary, and how demand and customer ordering patterns develop.
- Progress on HIS integration, expected benefits, remaining costs, and whether the planned capital spending supports profitable growth.
- Earn-out performance assumptions and potential cash exposure of up to $225 million, alongside the reported $47.5 million liability.
- Developments in the antitrust litigation, government investigations, and Pfizer indemnification claims.
- Cash conversion, working-capital trends, and the effect of ASC 606 timing differences when comparing reported periods.